{"schema_version":"secwatch.filing_event.v1","accession":"0000883984-24-000004","form_type":"8-K","ticker":"ICUI","cik":"0000883984","company_name":"ICU MEDICAL INC/DE","filed_at":"2024-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.135321+00:00","generated_at":"2026-06-05T13:52:12.883288+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"medium","headline":"ICU Medical Q4 revenue up slightly but net loss widens; provides FY2024 guidance","bullets":["Revenue $587.9M in Q4 2023, up 1.7% YoY from $578.0M.","GAAP net loss $17.1M ($0.71/share) widened from $15.5M loss ($0.65/share) in Q4 2022.","Adjusted EBITDA $86.3M vs $96.4M YoY; adjusted EPS $1.57 vs $1.60.","Gross margin slipped to 29% from 30%; gross profit $171.6M vs $174.9M.","Company issued FY2024 guidance (not detailed in excerpt)."],"urls":{"canonical":"https://secwatch.observer/filing/0000883984-24-000004","json":"https://secwatch.observer/filing/0000883984-24-000004.json","markdown":"https://secwatch.observer/filing/0000883984-24-000004.md","text":"https://secwatch.observer/filing/0000883984-24-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/883984/000088398424000004/0000883984-24-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/883984/000088398424000004/icui-20240227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T13:52:12.883288+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9ddf449544d0335d304092bda7253c84257ffdf3","claim":"ICU MEDICAL INC/DE reported fourth quarter of 2023 results: revenue $587.9 million, net income $(17.1) million, EPS $(0.71) per diluted share.","evidence_excerpt":"and sale of innovative medical products, today announced financial results for the quarter ended December 31, 2023. Fourth Quarter 2023 Results Fourth quarter 2023 revenue was $587.9 million, compared to $578.0 million in the same period in the prior year. GAAP gross profit for the fourth quarter of 2023 was $171.6 million, as compared to $174.9 million in the same","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/883984/000088398424000004/0000883984-24-000004-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter of 2023"},{"label":"Revenue","value":"$587.9 million"},{"label":"Net income","value":"$(17.1) million"},{"label":"EPS","value":"$(0.71) per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}